BioMark Diagnostics Inc. is proud to announce that it has obtained NSERC Engage Grant partnership funding in collaboration with Dr. David Wishart, Director of The Metabolomics Innovation Centre (TMIC) at the University of Alberta.
President and CEO Rashid Ahmed says, “We are delighted to enhance our collaboration with Dr. Wishart and TMIC at the University of Alberta. The collaboration to research, validate and establish additional biomarkers with a premier metabolic institution is testimony on the importance of metabolic tests for clinical and diagnostic applications. Dr. Wishart’s expertise and TMIC’s infrastructure offers BioMark an ideal partnership.” BioMark acknowledges and is thankful for the continued support and commitment from Natural Sciences and Engineering Research Council of Canada.
The Metabolomics Innovation Centre (TMIC) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes nearly $20 million in state-of-the-art metabolomics equipment and ongoing investment for “omics” research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMIC’s technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications such as human health and disease, petroleum research, forensics, food and nutrition, anti-doping, and textile sciences. TMIC provides access to cutting-edge metabolomic and bioinformatics technologies for Genome Canada-funded projects and the broader research community including government, academia and industry. For more information, visit www.metabolomicscentre.ca.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.
The CSE has not reviewed, approved or disapproved the content of this press release.
Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer